PrismRA转发了
Scipher Medicine and Roivant Sciences today announced a strategic partnership to advance rheumatology drug discovery and development by integrating Scipher’s real-world clinical and genomic data insights into Roivant’s research and development efforts. This collaboration will leverage Scipher's unique data and intelligence derived from its PrismRA precision medicine diagnostic. ? Scipher's PrismRA test uses 19 genomic markers to identify patients who are unlikely to respond to specific rheumatoid arthritis therapies, enabling personalized treatment decisions. By integrating data and insights derived from the development and commercialization of PrismRA, Roivant will leverage a unique and powerful data asset to inform its drug development pipeline. Link: https://lnkd.in/eWUdP8Gz #PrecisionMedicine #AutoimmuneDisease #RheumatoidArthritis #RealWorldEvidence #ArtificialIntelligence